Impact of MYC and BCL2 double expression on outcomes in primary CNS lymphoma: a UK multicenter analysis.

Saved in:
Bibliographic Details
Title: Impact of MYC and BCL2 double expression on outcomes in primary CNS lymphoma: a UK multicenter analysis.
Authors: Poynton E; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.; Department of Clinical Haematology, University College London Hospital, London, United Kingdom., Chernucha E; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom., Day J; Department of Clinical Haematology, University College London Hospital, London, United Kingdom., Prodger C; Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Centre, Oxford, United Kingdom., Hopkins D; Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom., Rakesh P; Centre for Clinical Haematology, University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom., O'Neill T; Department of Haemato-Oncology, St. Bartholomew's Hospital, Barts Health NHS Trust, London, United Kingdom., Thakrar N; Department of Clinical Haematology, University College London Hospital, London, United Kingdom., Akarca A; Department of Histopathology, University College London Hospital, London, United Kingdom., Jamal E; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom., Ali A; Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom., Kirkwood AA; Cancer Research UK and UCL Cancer Trial Centre, UCL Cancer Institute, University College London, London, United Kingdom., Pomplun S; Department of Histopathology, University College London Hospital, London, United Kingdom., Marafioti T; Department of Histopathology, University College London Hospital, London, United Kingdom., Calaminici M; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom., Greaves P; Department of Haematology, Barking Havering and Redbridge University Hospital NHS Trust, Romford, United Kingdom., Chaganti S; Centre for Clinical Haematology, University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom., McKay P; Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom., Smith J; Clatterbridge Cancer Centre, Liverpool University Hospitals, Liverpool, United Kingdom., Eyre TA; Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Centre, Oxford, United Kingdom., Martinez-Calle N; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom., Cwynarski K; Department of Clinical Haematology, University College London Hospital, London, United Kingdom., Fox CP; School of Medicine, University of Nottingham, Nottingham, United Kingdom., Okosun J; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
Source: Blood advances [Blood Adv] 2024 Apr 09; Vol. 8 (7), pp. 1772-1775.
Publication Type: Multicenter Study; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2473-9537
DOI:10.1182/bloodadvances.2023011426